SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as it faces a patent infringement lawsuit from Novo Nordisk and intense FDA/DOJ scrutiny over its compounded GLP-1 weight-loss offerings, sparking a significant sell-off and heated community debate about management's decisions and potential for a short squeeze.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending as its merger target, Infleqtion, gained significant attention for securing a NASA space mission and a DOE contract, with the community highly anticipating the upcoming merger vote on February 12th and NYSE debut as INFQ on February 17th. Investors are actively discussing Infleqtion's perceived undervaluation compared to quantum peers, emphasizing its superior neutral-atom technology and established government contracts in defense, space, and energy as key drivers for substantial upside post-merger.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart's imminent earnings report is sparking intense debate among investors, with strong convictions for both significant upside and downside moves. The community is also closely watching how potential credit card interest rate caps and the broader fintech market could influence the AI-powered lending platform's outlook.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is actively trending following positive Phase 2a trial results for its atopic dermatitis drug, EVO301, prompting analysts to significantly raise price targets. The news has sparked a lively debate among traders, with many anticipating further upside and a potential short squeeze, while others expect profit-taking and caution against volatility.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as new AI-powered financial tools, notably Altruist's tax planning offering, are sparking investor fears of significant disruption and fee compression across the wealth management sector. The community is split, with some seeing this as an exaggerated market reaction and a buying opportunity, while others worry about the company's ability to adapt swiftly.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Robust positive 52-week maintenance data for Nektar Therapeutics' atopic dermatitis drug, rezpegaldesleukin, is driving significant analyst upgrades and community discussions around a major valuation re-rate, given its durable responses and strong safety profile. Investors are also actively speculating on a potential short squeeze or a significant settlement/buyout, particularly with ongoing litigation with Lilly.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its Q4 earnings report showed profitability but cautious 2026 guidance and a strategic exit from a business line, triggering a substantial sell-off. The community is vigorously debating whether the market's reaction is an unjustified manipulation of an undervalued stock or a reflection of management's prudent risk management within a challenging fintech landscape.

S&P Global, Inc. engages in the provision of transparent and independent ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. It operates through the following segments: Market Intelligence, Ratings, Commodity Insights, Mobility, Indices, and Engineering Solutions. The Market Intelligence segment provides multi-asset-class data and analytics integrated with purpose-built workflow solutions. The Ratings segment is involved in credit ratings, research, and analytics, offering investors and other market participants information, ratings, and benchmarks. The Commodity Insights segment focuses on information and benchmark prices for the commodity and energy markets. The Mobility segment offers solutions serving the full automotive value chain including vehicle manufacturers, automotive suppliers, mobility service providers, retailers, consumers, and finance and insurance companies. The Engineering Solutions segment engages in advanced knowledge discovery technologies, research tools, and software-based engineering decision engines to advance innovation, maximize productivity, improve quality, and reduce risk. The company was founded by James H. McGraw and John A. Hill in 1917 and is headquartered in New York, NY.

S&P Global Inc

S&P Global is trending lower after its cautious outlook reinforced market fears that AI-powered tools will disrupt traditional financial information services. The community is sharply divided, debating if this signals a fundamental shift for a high-quality name or an overblown reaction creating a compelling buying opportunity.

Ichor Holdings Ltd. engages in designing, engineering, and manufacturing fluid delivery subsystems for semiconductor capital equipment. It offers gas and chemical delivery systems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The firm also manufactures precision machined components, weldments, and proprietary products for use in fluid delivery systems for direct sales to its customers. The company was founded in 1999 and is headquartered in Fremont, CA.

Ichor Holdings Ltd

Ichor Holdings is trending following strong Q4 2025 earnings and optimistic 2026 guidance, which points to strengthening demand in the semiconductor capital equipment sector. The community is actively discussing ICHR as a key "pick and shovel" play in the memory and AI-driven chip manufacturing landscape, though some warn the stock is overextended.

Gilat Satellite Networks Ltd. engages in the provision of broadband satellite communication and networking solutions and services. It operates through the following business segments: Fixed Networks, Mobility Solutions, and Terrestrial Infrastructure Projects. The Fixed Networks segment provides advanced fixed broadband satellite communication networks, satellite communication systems and associated professional services and comprehensive turnkey solutions and fully managed satellite network services solutions. The Mobility Solutions segment provides advanced on-the-move satellite communications equipment, systems, and solutions, including airborne, maritime and ground-mobile satellite systems and solutions. The Terrestrial Infrastructure Projects segment provides network infrastructure construction of the fiber and microwave network of PRONATEL in Peru. The company was founded by Yoel Gat, Gideon Kaplan, Amiram Levinberg, Joshua Levinberg, and Shlomo Tirosh in 1987 and is headquartered in Petah Tikva, Israel.

Gilat Satellite Networks

Gilat Satellite Networks is trending due to its recent Q4 and full-year 2025 earnings, which, despite strong revenue growth and positive 2026 guidance, led to a sharp stock price decline. The community views this as an overreaction, with many actively buying the dip and highlighting the company's strong pipeline of contracts in the burgeoning satellite communication and defense markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from BTIG Research

BTIG Research reaffirmed a "buy" rating and issued a $138.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Buy" by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been given a consensus recommendation of "Buy" by the twenty-two brokerages that are presently covering the company, Marketbeat Ratings...

Knights of Columbus Asset Advisors LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR

Knights of Columbus Asset Advisors LLC bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to the company in its most recent...

Federated Hermes Inc. Makes New Investment in Kymera Therapeutics, Inc. $KYMR

Federated Hermes Inc. bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to its most recent filing with the Securities...

KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate

Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.

Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)

BTIG Research Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR)

BTIG Research reaffirmed a "buy" rating and set a $138.00 price target on shares of Kymera Therapeutics in a research note on Thursday...

Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why

Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?

KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.

Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3% - What's Next?

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 4.3% - What's Next...

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

KYMR
Kymera Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KYMR News

KYMRKymera Therapeutics Inc